Format

Send to

Choose Destination
Clin Cancer Res. 2016 Sep 15;22(18):4687-97. doi: 10.1158/1078-0432.CCR-15-3133. Epub 2016 Apr 22.

Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.

Author information

1
New Therapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain.
2
Oklahoma Medical Research Foundation, Program in Immunobiology and Cancer, Oklahoma City, Oklahoma.
3
New Therapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain. Medical Oncology Department, Catalan Institute of Oncology (ICO) and Girona Biomedical Research Institute, Girona, Spain.
4
New Therapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain. Pathology Department, Dr. Josep Trueta Hospital and Catalan Institute of Health (ICS), Girona, Spain.
5
Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
6
New Therapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain. teresa.puig@udg.edu.

Abstract

PURPOSE:

Triple-negative breast cancer (TNBC) lacks an approved targeted therapy. Despite initial good response to chemotherapy, 30% of the patients relapse within 5 years after treatment. EGFR overexpression is a common marker in TNBC, and its expression has been correlated with poor outcome. Inhibition of fatty acid synthase (FASN) activity leads to apoptosis of human carcinoma cells overexpressing FASN. We tested the hypothesis that blocking FASN in combination with anti-EGFR signaling agents would be an effective antitumor strategy in sensitive and chemoresistant TNBC.

EXPERIMENTAL DESIGN:

Several TNBC cell lines and 29 primary tumors were included to determine whether FASN is a potential target in TNBC. Doxorubicin-resistant TNBC cell lines (231DXR and HCCDXR) have been developed and characterized in our laboratory. Cellular and molecular interactions of anti-FASN compounds (EGCG and C75) with cetuximab were analyzed. In vivo tumor growth inhibition was evaluated after cetuximab, EGCG, or the combination in TNBC orthoxenograft models.

RESULTS:

TNBC cell lines showed overexpression of FASN enzyme and its inhibition correlated to FASN levels. FASN staining was observed in all of the 29 TNBC tumor samples. In vitro, EGCG and C75 plus cetuximab showed strong synergism in sensitive and chemoresistant cells. In vivo, the combination of EGCG with cetuximab displayed strong antitumor activity against the sensitive and chemoresistant TNBC orthoxenografts, without signs of toxicity.

CONCLUSIONS:

Our results show that the simultaneous blockade of FASN and EGFR is effective in preclinical models of sensitive and chemoresistant TNBC. Clin Cancer Res; 22(18); 4687-97. ©2016 AACR.

PMID:
27106068
DOI:
10.1158/1078-0432.CCR-15-3133
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center